SciFluor Life Sciences, a Cambridge-based division of Allied Minds, has raised $30 million in funding to get its fluorine-based candidates into the clinical trial phase. The top two drugs are SF0166 (designed to combat age-related macular degeneration and diabetic macular edema) and SF0034 (small-molecule therapy to treat epilepsy). The funding comes from the generosity of Invesco, Woodford Investment Management and Allied Minds.

SciFluor has also tapped William Koster to serve as chairman. Koster is the former Neurogen CEO and Bristol-Myers Squibb executive, who will work to lead SciFluor in the next stage of the company’s evolution.

FULL STORY